New study investigates Wegovy's safety in pregnancy
NCT ID NCT05503927
First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times
Summary
This study looks at health records of about 1,100 women who took Wegovy during pregnancy and compares them to those who did not. The goal is to see if the drug increases risks for birth defects or other problems in babies. Researchers will use insurance claims data to track outcomes like major birth defects and low birth weight.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
IBM Watson Health™ Truven Marketscan
Ann Arbor, Michigan, 48108, United States
-
Novo Nordisk Investigational Site
Princeton, New Jersey, 08540, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?